TGFB1 and idiopathic pulmonary fibrosis: SfA (1 μM) treatment did not modulate IPF fibroblast contractility — assessed by αSMA protein levels — or TGF-β1/SMAD signaling (Figure 6, J and K, and Supplemental Figure 11).